Evidence map›Paper›PMID 40247619›Full record

ArticleBiophysical journal2025

Active and inactive pathways in the kinetic mechanism of the G51V retinitis pigmentosa mutant photoreaction.

Istvan Szundi, Weekie Yao, Eefei Chen, David S Kliger, David L Farrens

Abstract read
In one paragraph

Article in Biophysical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Istvan SzundiDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, California.
Weekie YaoDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, Oregon.
Eefei ChenDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, California.
David S KligerDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, California. Electronic address: kliger@ucsc.edu.
David L FarrensDepartment of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, Oregon. Electronic address: farrensd@ohsu.edu.

Funding

Structural Dynamics in Rhodopsin Activation and AttenuationR01EY029343 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI David L Farrens · 2019 to 2026
$2.9M
NEI NIH HHS R01 EY029343
6 · The paper itself

Abstract

Autosomal dominant retinitis pigmentosa is a visual disorder that can result from many different mutations of the rhodopsin gene. In most cases the mutation results in a misfolded rhodopsin protein or a protein that does not bind with the retinal chromophore. Some mutations, however, yield rhodopsins which fold properly and bind the retinal chromophore, yet still result in autosomal dominant retinitis pigmentosa. Here, we investigate the activation mechanism of one such mutation that produces the G51V rhodopsin variant. Human WT and G51V were recombinantly produced and embedded in identical nanodisks. Time-resolved spectra were then measured from the nanosecond to second timescales across the near UV through the visible spectral ranges. From these measurements the activation mechanisms of the two proteins were compared. While studies of the WT protein yielded a mechanism consistent with previous determinations of human rhodopsin, the G51V mechanism involved multiple pathways. These results suggest multiple ways for the protein to fold, some of which are photoactivated while the majority do not activate normally.

Indexed as

LightMutationPhotochemical ProcessesRetinitis PigmentosaRhodopsinHumansKineticsMutant ProteinsMutant ProteinsRhodopsin

Identifiers

PMID40247619
PMCPMC12242434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.